Sugi Predict

Sugi Predict / Compounds / SCHEMBL4689028

SCHEMBL4689028

SCHEMBL4689028

COC(=O)c1c(Cl)ccc([N+](=O)[O-])c1N

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 4/20 0.44
▸ MAPT P10636 3/20 0.44
▸ POLB P06746 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ LMNA P02545 4/20 0.43
▸ KMT2A Q03164 5/20 0.43
▸ ALDH1A1 P00352 4/20 0.43
▸ HPGD P15428 2/20 0.43
▸ MAPK1 P28482 2/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ ABCC4 O15439 1/20 0.43
▸ PLIN1 O60240 1/20 0.43
▸ CACNA1F O60840 1/20 0.43
▸ GMNN O75496 1/20 0.43
▸ KCNK2 O95069 1/20 0.43
▸ ABCB11 O95342 1/20 0.43
▸ GSR P00390 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ CYP1A2 P05177 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16862940 0.86 TDP1 (0.47) TDP1MAPTPOLBHTTLMNA
SCHEMBL4695615 0.84 TDP1 (0.53) TDP1MAPTPOLBHTTLMNA
SCHEMBL3710523 0.83 KMT2A (0.52) TDP1MAPTPOLBHTTLMNA
SCHEMBL1071311 0.82 KMT2A (0.43) TDP1MAPTHTTLMNAKMT2A
SCHEMBL1069184 0.82 TDP1 (0.53) TDP1MAPTPOLBHTTLMNA
SCHEMBL28416780 0.82 TDP1 (0.44) TDP1MAPTPOLBHTTLMNA
SCHEMBL5635837 0.81 TDP1 (0.53) TDP1MAPTPOLBHTTLMNA
SCHEMBL6137887 0.81 TDP1 (0.47) TDP1MAPTHTTLMNAKMT2A
SCHEMBL21986735 0.81 TDP1 (0.43) TDP1MAPTPOLBHTTLMNA
SCHEMBL1072166 0.81 HCAR3 (0.46) TDP1MAPTPOLBHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4499630-A1 BCL-XL INHIBITORS BeiGene, Ltd. (KY) 2025-02-05 — — EP disclosed
US-20250034128-A1 BCL-XL INHIBITORS BEIGENE, LTD. (KY) 2025-01-30 — — US disclosed
CN-118974033-A Bcl-xL inhibitors 百济神州有限公司 2024-11-15 — — CN disclosed
EP-3660003-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2024-01-24 — — EP disclosed
WO-2023185986-A1 BCL-XL INHIBITORS BEIGENE , LTD. (KY) 2023-10-05 — — WO disclosed
US-11713311-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-08-01 — — US disclosed
US-20220388995-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-12-08 — — US disclosed
US-11230541-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-01-25 — — US disclosed
US-20200231579-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-07-23 — — US disclosed
EP-3660003-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2020-06-03 — — EP disclosed
US-20070225317-A1 RSV POLYMERASE INHIBITORS SIMONEAU BRUNO 2007-09-27 — — US disclosed
US-20070225317-A1 RSV POLYMERASE INHIBITORS SIMONEAU BRUNO 2007-09-27 — — US disclosed
US-20070225317-A1 RSV POLYMERASE INHIBITORS SIMONEAU BRUNO 2007-09-27 — — US disclosed
EP-1682547-A1 RSV POLYMERASE INHIBITORS BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2006-07-26 — — EP disclosed
US-20050239814-A1 RSV polymerase inhibitors BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2005-10-27 — — US disclosed
EP-1515956-A4 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM (US) 2005-08-10 — — EP disclosed
WO-2005042530-A1 RSV POLYMERASE INHIBITORS BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2005-05-12 — — WO disclosed
WO-2005042530-A1 RSV POLYMERASE INHIBITORS BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2005-05-12 — — WO disclosed
EP-1515956-A1 PEPTIDE DEFORMYLASE INHIBITORS Smithkline Beecham (US) 2005-03-23 — — EP disclosed
WO-2003104209-A1 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-12-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11230541-B2 Heterocyclic compound GRIN1, GRIN2A, GRIN2B TDP1 1434/4885MAPT 213/4885POLB 2761/4885
US-20200231579-A1 HETEROCYCLIC COMPOUND GRIN1, GRIN2A, GRIN2B TDP1 1434/4885MAPT 213/4885POLB 2761/4885
US-11713311-B2 Heterocyclic compound GRIN1, GRIN2A, GRIN2B TDP1 1434/4885MAPT 213/4885POLB 2761/4885
US-20250034128-A1 BCL-XL INHIBITORS BCL2, BCL2L1, BCL2L10 TDP1 3212/4885MAPT 2642/4885POLB 1598/4885
US-20070225317-A1 RSV POLYMERASE INHIBITORS POLR2E, POLR2H, POLR2A TDP1 1766/4885MAPT 3709/4885POLB 17/4885
US-20220388995-A1 HETEROCYCLIC COMPOUND GRIN1, GRIN2A, GRIN2B TDP1 1434/4885MAPT 213/4885POLB 2761/4885
US-20050239814-A1 RSV polymerase inhibitors POLR2E, POLR2H, POLR2A TDP1 1766/4885MAPT 3709/4885POLB 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.